Canopy Growth (CGC) Cash from Financing Activities (2019 - 2025)
Canopy Growth's (CGC) quarterly Cash from Financing Activities came in at $65.5 million in Q4 2025, up 404.0% year-on-year from $13.0 million in Q4 2024, and down 46.66% quarter-over-quarter from $122.8 million in Q3 2025.
Canopy Growth (CGC) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Canopy Growth has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $65.5 million for Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $65.5 million, up 404.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $195.6 million (up 53.65% YoY), and the FY2025 annual result was $103.6 million, up 130.02% from the prior year.
- Cash from Financing Activities came in at $65.5 million for Q4 2025 at Canopy Growth, down from $122.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $786.6 million in Q1 2021 to a low of -$204.5 million in Q3 2023.
- The 5-year median for Cash from Financing Activities is -$273368.7 (2021), against an average of $35.3 million.
- Across the five-year window, Cash from Financing Activities plunged 36245.01% in 2022 and surged 14591.67% in 2023, its largest moves.
- Canopy Growth's Cash from Financing Activities stood at $272114.3 in 2021, then tumbled by 36245.01% to -$98.4 million in 2022, then surged by 50.54% to -$48.6 million in 2023, then soared by 55.71% to -$21.5 million in 2024, then jumped by 404.0% to $65.5 million in 2025.
- The last three Cash from Financing Activities figures came in at $65.5 million (Q4 2025), $122.8 million (Q3 2025), and $18.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn | 65.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.50 Mn |
| Dec 31, 2025 | 65.50 Mn |
| Sep 30, 2025 | 122.80 Mn |
| Sep 30, 2025 | 122.80 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Mar 31, 2025 | -11.12 Mn |
| Mar 31, 2025 | -11.12 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Dec 31, 2024 | -21.55 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Sep 30, 2024 | 65.20 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Jun 30, 2024 | 77.34 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Dec 31, 2023 | -48.65 Mn |
| Sep 30, 2023 | -204.53 Mn |
| Sep 30, 2023 | -204.53 Mn |